MTX-531 is an oral drug that inhibits EGFR and PI3K isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). It has anti-tumor effects and acts as a weak agonist of PPARγ, which helps mitigate hyperglycemia often induced by PI3K inhibitors. It shows excellent tolerance in mice and has demonstrated concentration-dependent inhibitory effects on EGFR, P13K, and mTOR in CAL-33 cells.
- Inhibits EGFR and PI3K isoforms
- Acts as a weak agonist of PPARγ, alleviating PI3K inhibitor-induced hyperglycemia
- Demonstrates anti-tumor activity in various models
- Administered orally
- Shows excellent tolerance in mice